Successful Control of Hypoglycemia with Pasireotide LAR in a Patient with Inappropriate Insulin Secretion.

Fiche publication


Date publication

janvier 2021

Journal

Clinical pharmacology : advances and applications

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PETIT Jean-Michel, Pr VERGES Bruno


Tous les auteurs :
Rouland A, Bouillet B, Legris P, Simoneau I, Petit JM, Vergès B

Résumé

Inappropriate insulin secretion could be due to several diseases. Nesidioblastosis is characterized by diffuse hyperplasia of pancreatic beta cells, causing organic hypoglycemia. No pancreatic lesions are found on the imaging of patients with this condition. Diazoxide is used as a first-line treatment but can be poorly tolerated because of its side effects, and therapeutic failure is possible. Somatostatin analogues have limited efficacy because of their poor affinity to somatostatin (SST) receptors. Pasireotide is a somatostatin analogue with a much higher affinity to SST receptors, especially SST5, and it could thus be more efficient for treating nesidioblastosis-related hypoglycemia.

Mots clés

diazoxide, hypoglycemia, nesidioblastosis, pasireotide LAR

Référence

Clin Pharmacol. 2021 ;13:33-37